For Tuesday, February 7th
SRGE, FORC, CSOC, SNDY, CYCA, ENMD
Our Stocks to Watch tomorrow include Southridge Enterprises Inc. (OTC: SRGE), Force Energy Corp. (OTCBB: FORC), Caduceus Software Systems Corp. (OTCBB: CSOC), Solos Endoscopy Inc. (OTC: SNDY), Cytta Corp. (OTCBB: CYCA) and EntreMed Inc. (Nasdaq: ENMD).
SOUTHRIDGE ENTERPRISES (OTC: SRGE)
"Up 127.27% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/SRGE.php
Southridge Enterprises, Inc. operates as a renewable energy company. It primarily focuses on the production and marketing of ethanol and other renewable fuels in the eastern United States. The company was founded in 2004 and is headquartered in Dallas, Texas.
SRGE News:
January 30 - Southridge to Decrease Total Outstanding Shares by Over 18%
Southridge Enterprises Inc. (OTC: SRGE) ("Southridge" or the "Company") announced that it will be retiring 150 million shares. This transaction represents a reduction of approximately 18% of the Company's issued and outstanding common shares.
Michael Davies, the Company's President, commented, "By decreasing the total outstanding shares by over 18%, we intend to increase future earnings per share and allow our share price to more accurately represent the quality and profit potential of our assets and operations to the investment community."
As previously announced on November 08, 2011, the acquisitions of stock under the repurchase plan will be made from time to time as permitted by securities laws and corporate legal requirements and subject to market conditions and other factors. Share purchases will be funded by the Company's cash and through debt financing. The repurchase plan will continue as long as periodic management reviews deem it to be fiscally feasible and the plan may be discontinued at any time.
FORCE ENERGY CORPORATION (OTCBB: FORC)
"Up 133.33% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/FORC.php
Force Energy Corporation (FORC) is a Lithium, Rare Earth and Hydrocarbon Exploration and Development Company based in Denver, Colorado. Force Energy plans to explore and develop its Zoro 1 Lithium property located in the Snow Lake area of west-central Manitoba, Canada. Force Energy also maintains a 50% working interest in the Hayter Well, a Hydrocarbon well located in Alberta, Canada.
FORC News:
February 6 - Force Energy Obtains Drill Permit for Zoro 1 Property
Force Energy Corp. (OTCBB: FORC) (hereafter "Force", "the Company"), a junior Lithium and Rare Earth Metals mineral exploration company, is pleased to announce it has been granted a drill permit for the Zoro 1 Property by the Manitoba Conservation Office in Snow Lake, MB.
The permit authorizes Force to carry out a diamond drilling operation on the property. This initial diamond drilling program is a necessary evaluation of the Zoro 1 Property in order to examine the third dimension of the potential resource. Results of this program are intended to determine whether the confirmed historic resource of 1.7 million tons of lithium grading 0.95%Li20 can be mined economically.
"We are pleased to work with the efficient people of the Manitoba Conservation Office and thank them for their timeliness in authorizing this work permit," says Mr. Tim DeHerrera, president of Force Energy Corp. "The fact that the pegmatite and combined lithium comes to surface and has a historic resource established is extremely encouraging, and we look forward to examining core samples to confirm the third dimension of this resource and determine economic viability of the project."
CADUCEUS SOFTWARE SYSTEMS CORPORATION (OTCBB: CSOC)
"Up 51.83% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/CSOC.php
Caduceus Software Systems Corp. is a software company that specializes in developing an all-in-one solution for private practitioners and doctors. We are in the healthcare information management industry. We are headquartered in the United Kingdom, specifically located in the metropolitan city of Birmingham. Our company was created as we saw an urgent need for better patient care throughout the world. General practitioners are using unsophisticated software which acts as a more administrative than acting as a time saving tool. We are called Caduceus, which is the well-known insignia used by medical professionals.
CSOC News:
February 6 - Caduceus Software Systems Corp. Plans to Integrate a Cloud Platform with its Software Systems; Health Records in the Cloud called 'Next Big Thing'
Caduceus Software Systems Corp. (OTCBB: CSOC) (The Company) informs the public of some of its current project and software undertakings. The Company's flagship product, Caduceus MMS version 1.0, is an all-in-one software solution for medical offices which practitioners and medical clerks can use to manage patient bookings, patient private diagnoses and data (also known as Electronic Health Records, or EHR), and process billing (also known as Electronic Medical Billing, or EMB).
The Company believes its cloud computing undertaking is well positioned to take advantage of the demand for cloud services. For example articles such as the following have been written that called the move of health records to the cloud as the "next big thing."
The current platform is an application which installs onto the office computer terminals and the clerks and practitioner can access it within their private network. However, the Company is now exploring the ability to place the software in a "Cloud" platform, which means that the software is not installed on the private network, but rather installed on a dedicated server on the internet.
SOLOS ENDOSCOPY INCORPORATED (OTC: SNDY)
"Up 30.77% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/SNDY.php
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions.
SNDY News:
No recent stories.
CYTTA CORPORATION (OTCBB: CYCA)
"Up 23.08% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/CYCA.php
Cytta Corp. does not have significant operations. The company holds a license to manufacture, sell, distribute, operate, sub-license, and market various technology-based Internet access, and computing products and services, which consist of Internet access devices, software and hardware, and various medical peripherals designed and adapted to provide remote non-diagnostic monitoring of home based and remote patients. It plans to develop these Internet access devices. Cytta Corp. was founded in 2006 and is based in Mill Valley, California.
CYCA News:
January 10 - Cytta Corp. President's Annual State of the Corporation Address
Erik Stephansen, president of Cytta Corp. (OTCBB: CYCA), addresses shareholders:
Transformation. Evolution. Revolution! These three words sum up the year 2011 for many others and us in the healthcare industry. As you may know, Cytta Corp. is trailblazing a solution to improve the care for chronically ill patients and those wishing to take charge of their care and, as President of Cytta, I'm proud to share with you the tremendous progress we made last year. Truly, it was a transformational year for us and for the healthcare industry as a whole.
Our nation began discussing healthcare in earnest and transformed the healthcare debate from a "when" conversation to a "how" conversation. Cytta Corp. has made it a "NOW" conversation.
At Cytta Corp., our desire to create health awareness transformed our company, our people, our partners and our customers. We entered the year with new ideas to make health awareness visible and a commitment to make a working system that generates health awareness. And, we did it!
Let me begin by acknowledging the very hard work our team has done over several years leading up to this last year. One could say we are an overnight success nearly a decade in the making. From our technology to our people, we leveraged these past efforts to produce our current industry paradigm shifting solution. Without these courageous prior efforts, we couldn't have made such great strides in 2011. Also, this evolutionary period spawned a health awareness awakening that the industry, Government, and consumers are now experiencing. Everywhere you look, people are talking about healthcare changes and possible improvements to delivering healthcare and wellness.
The technical advances in devices, communication and systems seemed to energize our partners and they were excited to work towards immediate solutions. Contract deliberations that could have taken months were resolved in days. After securing our own special purpose Medical Cellular Network, and joint venturing with Connected Health Pte, a unique developer of core mobile programming for the medical industry, we quickly signed joint venture agreements with leading manufactures such as A&D, Nonin, Entra Health Systems and others that wanted to share their FDA approved product advances to connect and empower patients. The result: Cytta Corp. together with our partners in telecom, security, software, and healthcare industries, created a new way for remote patient monitoring to serve those in need.
We call it CyttaConnect ™
Our revolutionary CyttaConnect system is fully operational and we deployed our first systems into the commercial market in October 2011.
CyttaConnect is a patient-caregiver wellness system that leverages our special purpose cellular network, branded wireless devices, smartphones and the CyttaConnect platform. As a wellness system, it builds an ecosystem of partners. Together, we promote health awareness and patient participation to enhance people's lives. By introducing CyttaConnect, the healthcare system for the first time will reward caregivers and patients by providing clear pathways to improve one's health. That's revolutionary!
We find this collaborative approach is paramount to tackling big issues and hard problems. Many said to fix the healthcare system, one needs to first improve and coordinate the care for chronically ill patients. In the US, this group of 50 million patients is rapidly growing and accounts for nearly 75% of all healthcare costs that reach over $2.5 trillion per year. In short, the chronically ill are the largest component of rising healthcare costs today.
There is a need to engage the patient, collect vital health metrics and generate new pathways to health awareness. Healthcare stakeholders want a connected system to collect and manage patient health metrics on an ongoing basis. Patients want a portable, low-cost and easy-to-use system that is responsive to their needs and supports an active lifestyle. CyttaConnect starts here.
The CyttaConnect wellness system resolves these issues. It is easy to use and utilizes any android smartphone combined with FDA approved state-of-the-art Bluetooth medical devices to move data over our cellular network at a very low cost.
CyttaConnect is the only system with auto-generated alerts. We collect near real-time patient readings, which are accessed in real time through our online CyttaDashboard technology. It is a super tool for Doctors, Nurse Case Managers and Caregivers to support their care regimens and track results. The CyttaConnect system is a two-way communication mechanism. It provides a coach-patient action cycle that supports the patient in his or her own environment.
***
Shifting gears to our business program, our business is solid. We successfully moved from a development stage company to a commerce organization. We are increasing our investment in technology and innovation. We are expanding and implementing a multi-pronged approach by leveraging direct and indirect marketing strategies.
We are managing our capital position to sustain good levels of capital, as well as overall balance sheet strength and flexibility. We are careful to support the business by controlling our expenses. Our people have a high level of personal commitment to improving healthcare and are working toward an equity position commensurate with their contributions in lieu of salaries. This helps keep our cash demands under control.
CyttaConnect's ecosystem is designed as a portfolio of products and services. We are actively working with more manufactures to provide devices and other services. The products and services we bring to market are more affordable in how they are designed and delivered and – as importantly – in how they perform for our customers. Our solutions provide higher quality, better information, and easier connectivity toward wellness, affordable care and care delivery.
***
As we mentioned earlier, there is a growing national will to solve core issues in the health care system around broader access, better and fairer use of resources and better connectivity and performance in care delivery. We take pride in offering a breakthrough mechanism to support this will and make it a reality.
We will develop additional innovative and complementary products, services and health approaches during this new deployment year. Our commitment is to combine our capabilities and our partners in practical ways to meet specific customer and market needs.
The changing healthcare and wellness demand is an opportunity that we are exceptionally well positioned to respond to and we leverage our partners as trusted resources that deliver real value. We are inspired to:
* Exceed consumer and customer expectations for ease of health data collection;
* Generate tools for the healthcare industry that patients can easily embrace to better their lives;
* Support the federal government by addressing the effectiveness and sustainability of its healthcare programs and generate well-being for all Americans.
We will continue to work across the health care system and promote our CyttaConnect solution to enable sustainable health communities that are connected, intelligent, aligned, and that achieve better health outcomes consistently for everyone.
On a last note, the opportunities for our system are expanding. Already, we have inquiries to utilize the CyttaConnect system beyond the chronically ill. In 2012, we will rollout the CyttaConnect system in a measured and controlled manner with specific partners who embrace the shifting landscape of healthcare. Our partners are supportive and eager to build on this early success.
In the coming months, we'll share more about our system and partners. Please know that we appreciate your support and your heartfelt commitment toward our efforts.
Leading our health revolution,
Erik the Wellness Viking
ENTREMED INCORPORATED (NASDAQ: ENMD)
"Up 20.43% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/ENMD.php
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.
ENMD News:
January 23 - EntreMed Secures $10 Million Strategic Financing
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P. ("IDG"), Emerging Technology Partners, LLC ("ETP"), and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.
The Company entered into purchase agreements with the investors, pursuant to which the Company has agreed to issue and sell to the investors convertible notes in the aggregate principal amount of $10 million. The investors also will be issued warrants covering a number of shares of common stock equal to 20% of the principal amount of the notes, divided by $1.15. The warrants are exercisable at $1.40 per share. The closing of the transaction is anticipated to occur on or about January 27, 2012 upon the satisfaction of certain conditions.
At the closing, IDG and ETP have the right to designate in the aggregate two members of the Company's Board of Directors. In addition, it is expected that the Company will select an interim Chief Executive Officer.
Subject to the approval of the Company's stockholders at the 2012 stockholder meeting, the notes will automatically and immediately convert into shares of common stock and the warrants will become exercisable. The notes have a maturity date of August 31, 2012, bear an interest rate of 6% and will convert at a conversion price of $1.15 per share. The conversion price reflects the 10-day average closing sale price ending on January 20, 2012. The notes are not convertible, and the warrants are not exercisable, prior to receiving stockholder approval. If stockholder approval is not obtained, the Company will be required to pay liquidated damages to the note purchasers equal to an aggregate of $1.2 million.
"We are very pleased to have the support from a group of knowledgeable investors and the validation of the potential of ENMD-2076. The proceeds from the notes will allow the Company to accelerate and expand its research and development activities, fund additional trials, initiatives and long term strategic plans," said Michael M. Tarnow, the Company's Executive Chairman.
After deducting transaction fees and expenses, the net proceeds to the Company will be approximately $9.3 million. The convertible notes, the warrants and the common stock into which the notes and warrants are convertible have not been registered under the Securities Act of 1933, as amended (the "Act") and applicable state securities laws, but have been offered and sold in the United States pursuant to applicable exemptions from registration requirements under the Act and applicable state securities laws. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.
ABOUT ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.
|
